5-羟色胺3受体拮抗剂ICS 205-930对原发性神经性厌食症患者胃排空和胃窦运动活性无系统性影响。

Lack of systematic effects of the 5-hydroxytryptamine 3 receptor antagonist ICS 205-930 on gastric emptying and antral motor activity in patients with primary anorexia nervosa.

Stacher G, Bergmann H, Granser-Vacariu G V, Wiesnagrotzki S, Wenzelabatzi T A, Gaupmann G, Kugi A, Steinringer H, Schneider C, Höbart J

Department of Psychiatry, University of Vienna, Austria.

Br J Clin Pharmacol. 1991 Dec;32(6):685-9.

Abstract

The 5-hydroxytryptamine 3 receptor antagonist, ICS 205-930, has been reported to have potent effects on gastric smooth muscle and to enhance gastric emptying in animals, but findings in man have been inconsistent. 2. This study investigated the effects of ICS 205-930 on gastric emptying of an isotopically labelled semisolid 1168 kJ meal and on antral contractility in patients with primary anorexia nervosa, a condition frequently associated with impaired gastric motor function. 3. Thirteen female patients (age 18-39 years, median 22 years; percentage of ideal body weight 52-90%, median 66%) participated each in two studies, in which 0.15-0.18 mg kg-1 ICS 205-930 or placebo were infused i.v. in crossover, double-blind fashion. Gastric emptying and antral contractility were recorded scintigraphically for 50 min. 4. ICS 205-930 did not affect gastric emptying: the mean percentage of meal remaining in the stomach after 50 min (69.6% +/- 3.2 s.e. mean) was nearly identical to that after placebo (70.7 +/- 3.3%). 5. Amplitude, frequency and propagation velocity of antral contractions differed only little after ICS 205-930 and placebo, respectively. 6. The results show that ICS 205-930 has no effect on the impaired gastric motor activity in primary anorexia nervosa and thus provide further evidence that the compound does not have prominent prokinetic effects in man.

摘要

据报道，5-羟色胺3受体拮抗剂ICS 205-930对胃平滑肌有强效作用，并能增强动物的胃排空，但人体研究结果并不一致。2. 本研究调查了ICS 205-930对原发性神经性厌食症患者经同位素标记的1168千焦半固体餐胃排空及胃窦收缩性的影响，原发性神经性厌食症常伴有胃运动功能受损。3. 13名女性患者（年龄18 - 39岁，中位数22岁；理想体重百分比52 - 90%，中位数66%）分别参与两项研究，以交叉、双盲方式静脉输注0.15 - 0.18毫克/千克体重的ICS 205-930或安慰剂。用闪烁扫描法记录50分钟的胃排空和胃窦收缩性。4. ICS 205-930不影响胃排空：50分钟后胃内剩余食物的平均百分比（69.6%±3.2标准误均值）与安慰剂组（70.7±3.3%）几乎相同。5. ICS 205-930和安慰剂作用后，胃窦收缩的幅度、频率和传播速度差异不大。6. 结果表明，ICS 205-930对原发性神经性厌食症受损的胃运动活动无影响，从而进一步证明该化合物在人体中没有显著的促动力作用。